1290 related articles for article (PubMed ID: 8845489)
1. Characteristics of the antitumor activity of M-16 and M-18, major metabolites of a new mitomycin C derivative KW-2149, in mice.
Ashizawa T; Okamoto A; Okabe M; Kobayashi S; Arai H; Saito H; Kasai M; Gomi K
Anticancer Drugs; 1995 Dec; 6(6):763-70. PubMed ID: 8845489
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of a derivative of mitomycin, 7-N-[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]mitomycin C (KW-2149), against murine and human tumors and a mitomycin C-resistant tumor in vitro and in vivo.
Tsuruo T; Sudo Y; Asami N; Inaba M; Morimoto M
Cancer Chemother Pharmacol; 1990; 27(2):89-93. PubMed ID: 2123421
[TBL] [Abstract][Full Text] [Related]
3. Antitumor activity of 7-N-[[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]]-mitomycin C.
Morimoto M; Ashizawa T; Ohno H; Azuma M; Kobayashi E; Okabe M; Gomi K; Kono M; Saitoh Y; Kanda Y
Cancer Res; 1991 Jan; 51(1):110-5. PubMed ID: 1988076
[TBL] [Abstract][Full Text] [Related]
4. Reduced bone marrow toxicity of KW-2149, a mitomycin C derivative, in mice.
Ashizawa T; Okabe M; Gomi K; Hirata T
Anticancer Drugs; 1993 Apr; 4(2):181-8. PubMed ID: 8490196
[TBL] [Abstract][Full Text] [Related]
5. Disposition and metabolism of KW-2149, a novel anticancer agent.
Kobayashi S; Ushiki J; Takai K; Okumura S; Kono M; Kasai M; Gomi K; Morimoto M; Ueno H; Hirata T
Cancer Chemother Pharmacol; 1993; 32(2):143-50. PubMed ID: 8485809
[TBL] [Abstract][Full Text] [Related]
6. Comparison of uptake of mitomycin C and KW-2149 by murine P388 leukemia cells sensitive or resistant to mitomycin C.
Kobayashi E; Okabe M; Kono M; Arai H; Kasai M; Gomi K; Lee JH; Inaba M; Tsuruo T
Cancer Chemother Pharmacol; 1993; 32(1):20-4. PubMed ID: 8096440
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of 7-n-(p-hydroxyphenyl)-mitomycin C in experimental tumor systems.
Imai R; Morimoto M; Marumo H; Kobayashi T; Tsuruo T; Inaba M; Tsukagoshi S; Sakurai Y
Gan; 1981 Dec; 72(6):944-9. PubMed ID: 6804296
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic characteristics and antitumor activity of the N-succinyl-chitosan-mitomycin C conjugate and the carboxymethyl-chitin-mitomycin C conjugate.
Song Y; Onishi H; Nagai T
Biol Pharm Bull; 1993 Jan; 16(1):48-54. PubMed ID: 8369752
[TBL] [Abstract][Full Text] [Related]
9. In vivo drug release and antitumor characteristics of water-soluble conjugates of mitomycin C with glycol-chitosan and N-succinyl-chitosan.
Sato M; Onishi H; Takahara J; Machida Y; Nagai T
Biol Pharm Bull; 1996 Sep; 19(9):1170-7. PubMed ID: 8889036
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity and toxicity in animals of N-7[2-(4-nitrophenyldithio) ethyl] mitomycin C (BMY-25067).
Bradner WT; Rose WC; Schurig JE; Florczyk AP
Invest New Drugs; 1990; 8 Suppl 1():S1-7. PubMed ID: 2380013
[TBL] [Abstract][Full Text] [Related]
11. In vivo properties of the conjugates of mitomycin C with estradiol benzoate and estradiol: pharmacokinetics and antitumor characteristics against P388 leukemia and sarcoma 180.
Ishiki N; Onishi H; Machida Y
Biol Pharm Bull; 1998 Nov; 21(11):1180-6. PubMed ID: 9853409
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of a novel antitumor antibiotic, quinocarmycin citrate (KW2152).
Fujimoto K; Oka T; Morimoto M
Cancer Res; 1987 Mar; 47(6):1516-22. PubMed ID: 2434218
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of antitumor activity of KW-2189, a novel water-soluble derivative of duocarmycin, against murine and human tumors.
Kobayashi E; Okamoto A; Asada M; Okabe M; Nagamura S; Asai A; Saito H; Gomi K; Hirata T
Cancer Res; 1994 May; 54(9):2404-10. PubMed ID: 8162588
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxic activity of 7-N-(2-((2-(-gamma-L-glutamylamino)- ethyl)dithio)ethyl)-mitomycin C and metabolites in cell lines with different resistance patterns.
Dirix LY; Gheuens EE; van der Heyden S; van Oosterom AT; De Bruijn EA
Anticancer Drugs; 1994 Jun; 5(3):343-54. PubMed ID: 7919460
[TBL] [Abstract][Full Text] [Related]
15. Mitomycin C combination therapy against murine tumor systems. Effectiveness with cyclophosphamide and methotrexate.
Mabel JA; Wodinsky I
Cancer; 1983 Feb; 51(4):600-5. PubMed ID: 6401590
[TBL] [Abstract][Full Text] [Related]
16. Comparative antitumor activities of 7-N-(p-hydroxyphenyl)mitomycin C (M-83) and mitomycin C.
Imai R; Morimoto M
J Antibiot (Tokyo); 1983 May; 36(5):559-65. PubMed ID: 6409871
[TBL] [Abstract][Full Text] [Related]
17. Phase I and pharmacokinetic study of a novel mitomycin C analog KW-2149.
Dirix L; Catimel G; Koier I; Provè A; Schrijvers D; Joossens E; De Bruijn E; Ardiet C; Evene E; Dumortier A
Anticancer Drugs; 1995 Feb; 6(1):53-63. PubMed ID: 7756684
[TBL] [Abstract][Full Text] [Related]
18. Antitumor activity of KW-2170, a novel pyrazoloacridone derivative.
Ashizawa T; Shimizu M; Gomi K; Okabe M
Anticancer Drugs; 1998 Mar; 9(3):263-71. PubMed ID: 9625437
[TBL] [Abstract][Full Text] [Related]
19. Modulation of sensitivity to mitomycin C and a dithiol analogue by tempol in non-small-cell lung cancer cell lines under hypoxia.
Bando T; Kasahara K; Shibata K; Numata Y; Heki U; Shirasaki H; Iwasa K; Fujimura M; Matsuda T
J Cancer Res Clin Oncol; 1996; 122(1):21-6. PubMed ID: 8543588
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and antitumor activity of novel mitomycin derivatives containing functional groups at the C-6-methyl position.
Arai H; Kanda Y; Ashizawa T; Morimoto M; Gomi K; Kono M; Kasai M
J Med Chem; 1994 Jun; 37(12):1794-804. PubMed ID: 8021918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
